S-1: Cyclacel Pharmaceuticals Seeks Up to $5 Million in Best Efforts Public Offering to Address Liquidity Concerns

Cyclacel Pharmaceuticals is launching a best efforts public offering of common stock and warrants to raise up to $5 million, primarily to address working capital needs and Nasdaq compliance issues.

Summary

• Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, has filed a Form S-1 registration statement for a best efforts public offering.
• The offering includes shares of common stock, common stock warrants, and pre-funded warrants, aiming to raise up to $5 million.
• Each common stock warrant allows the holder to purchase one share of common stock at an exercise price to be determined, expiring five years from the initial exercise date.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%, exercisable upon issuance at $0.0001 per share.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• Cyclacel anticipates that its existing cash and cash equivalents, along with the net proceeds from this offering, will satisfy its capital needs for a specified period, depending on the gross proceeds raised.
• The company faces challenges in raising capital and maintaining its Nasdaq listing due to its financial condition and going concern issues.
• Cyclacel's cash and cash equivalents as of June 30, 2024, were $6.0 million, but had decreased to approximately $2.8 million by September 27, 2024.
• The company received a notice from Nasdaq for non-compliance with the minimum stockholders' equity requirement and is appealing the Staff's decision to a Nasdaq hearings panel scheduled on October 15, 2024.
• The company's clinical programs include fadraciclib and plogosertib, both in Phase 1/2 trials for advanced solid tumors and lymphoma.
• The offering is expected to be completed within two business days following commencement, with securities delivered upon receipt of investor funds.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation for Cyclacel, with liquidity issues, Nasdaq compliance challenges, and reliance on a best efforts offering. While the company has clinical programs in development, the overall outlook is negative due to the financial risks.

Positives

• The company has two clinical-stage drug candidates, fadraciclib and plogosertib, in Phase 1/2 trials for advanced solid tumors and lymphoma.
• The company retains rights to commercialize its clinical development candidates and aims to enter into selective partnership arrangements.
• The offering includes pre-funded warrants for investors who would otherwise exceed beneficial ownership limits, providing flexibility for larger investors.

Negatives

• The company does not currently have sufficient funds to complete development and commercialization of any of its drug candidates.
• The company faces significant challenges in raising capital due to current market conditions and concerns about its ability to continue as a going concern.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement and faces potential delisting.
• The offering is a 'best efforts' offering, meaning there is no guarantee that the company will raise the full $5 million or any amount at all.
• The company's cash balance was approximately $2.8 million as of September 27, 2024, and it anticipates needing additional funding to continue operations beyond October 2024.

Risks

• The company may be unsuccessful in raising the capital necessary to address its going concern issues and comply with Nasdaq's stockholders' equity requirements.
• Failure to comply with Nasdaq's continued listing requirements could result in delisting, negatively impacting the price of the common stock and the company's ability to access capital markets.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value of the shares they purchase in this offering.
• There is no public market for the common stock warrants or pre-funded warrants being offered, limiting their liquidity.
• The placement agent has no obligation to purchase any of the securities from the company or to arrange for the purchase or sale of any specific number or dollar amount of the securities.

Future Outlook

The company anticipates that its existing cash and cash equivalents, along with the net proceeds from this offering, will satisfy its capital needs for a specified period, depending on the gross proceeds raised. However, there is no guarantee that the company will be able to raise additional funds on acceptable terms or at all to extend operations past October 2024.

Industry Context

The biopharmaceutical industry is capital-intensive, and clinical-stage companies often rely on external funding to advance their drug candidates. Cyclacel's situation reflects the challenges faced by many small-cap biotech firms in securing financing, particularly in volatile market conditions. Companies like Cyclacel are often compared to other small-cap biotech firms such as Veru Inc. and Aeterna Zentaris Inc. which have also recently announced public offerings to raise capital.

Comparison to Industry Standards

• Cyclacel's reliance on public offerings for funding is a common practice among clinical-stage biopharmaceutical companies.
• However, the company's current financial situation, with limited cash reserves and Nasdaq compliance issues, puts it at a disadvantage compared to peers with stronger balance sheets.
• Comparable companies, such as Veru Inc. and Aeterna Zentaris Inc., have also recently announced public offerings to raise capital, reflecting the ongoing need for funding in the biotech sector.
• The success of Cyclacel's offering will depend on investor confidence in its clinical programs and the potential for future partnerships.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares in the offering.
• Employees' job security is uncertain due to the company's financial challenges.
• The company's ability to continue clinical trials and develop new therapies depends on the success of the offering, impacting patients and the medical community.
• The company's ability to pay its creditors is uncertain due to the company's financial challenges.

Next Steps

• The company will proceed with the best efforts public offering to raise capital.
• The company will attend a Nasdaq hearings panel on October 15, 2024, to appeal the Staff's decision regarding non-compliance with the minimum stockholders' equity requirement.
• The company will continue to advance its clinical programs for fadraciclib and plogosertib.
• The company will seek potential partnership arrangements for its clinical development candidates.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, capital raise, Nasdaq, liquidity, biopharmaceutical, clinical trials, oncology